Our Mission

To discover and develop novel therapeutics that will stop the progression
of neurodegenerative diseases by targeting their underlying causes.

Our Programs

CURRENT CLINICAL TRIALS: NPT520-34 Phase 1 in Healthy Volunteers

News

Neuropore Initiates Phase 1 Clinical Trial in Healthy Volunteers with NPT520-34, a Therapeutic Candidate Aimed at Treating Parkinson’s Disease and Amyotrophic Lateral Sclerosis May 8, 2019

Neuropore Therapies, Inc. announced today that it has initiated a Phase 1 clinical trial in healthy volunteers with NPT520-34. This Phase 1 study is designed to evaluate the safety, tolerability and pharmacokinetics of NPT520-34.

See All News

Events

Neuropore Therapies (NPT™) CSO and Head of Program Management & Strategic Initiatives will be present at BIO International Convention 

June 3rd-6th, 2019  in Philadelphia, PA USA

See All Events

NPT® Publications

Neuropore publishes paper describing the preclinical in vivo characterization of a small molecule compound targeting α-synuclein as a potential Parkinson's disease therapeutic
November 2nd, 2018

Report in Scientific Reports, describes the beneficial effects of NPT200-11 on multiple disease relevant endpoints in a transgenic mouse model of Parkinson's disease.

See All Publications

 

 

A team poised for success

About Our Team

Our Partners




Corporate

UCB Logo


Foundations & Academic InstitutionsSEE ALL

The Michael J. Fox Foundation for Parkinson's Research
Albert Einstein College of Medicine
University of Sydney

Connect with Neuropore